Sanaria researchers make progress in the development of highly protective malaria vaccine
Researchers from Sanaria
® Inc. and the National Institutes of Health (NIH) are making progress in the development of highly protective malaria vaccines.
In an article published today in
Nature, Sanaria s PfSPZ-CVac (CQ) vaccine is reported as being safe and protecting 100% of six subjects against a variant malaria parasite three months after their last dose in the company s Phase 1 safety and efficacy trial. This is the first time complete protection against a variant malaria parasite has ever been achieved that long after vaccine administration.
The variant parasite used in the trial is a Brazilian malaria parasite genetically more variant from the African parasites in the vaccine than 700 malaria parasites from Africa. Protection was achieved at a dose that is 20% of the company s first-generation malaria vaccine dosage.
Long COVID afflicts kids too Here s what we know so far
nationalgeographic.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from nationalgeographic.com Daily Mail and Mail on Sunday newspapers.
Sanaria Vaccine trial results demonstrate unprecedented progress in worldwide battle against variant malaria parasites
pulse.ng - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pulse.ng Daily Mail and Mail on Sunday newspapers.